ReviewClinical neuroradiology2026
Carotid Artery Stenting vs Endarterectomy Across Procedural Eras : A Systematic Review and Meta-Analysis.
Review in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCarotid artery stenting (CAS) and carotid endarterectomy (CEA) are established revascularization strategies, but randomized evidence has often been interpreted without accounting for major changes in CAS technique. We assessed whether the comparative 30-day safety of CAS and CEA differs when trials are stratified by early-device versus contemporary embolic-protected procedural eras.
methodsPubMed, Embase and the Cochrane Library were searched from inception to 1 December 2025 for randomized trials of carotid revascularization in extracranial carotid stenosis. The prespecified novelty of this meta-analysis was era-based stratification according to CAS procedural standards: early-device trials (≤ 2010) versus contemporary embolic-protected CAS trials (≥ 2011), defined by operator credentialing, routine embolic protection, protocolized antiplatelet therapy and contemporary stent platforms. Direct CAS-CEA comparisons were pooled within era-specific strata; trials comparing revascularization with intensive medical therapy were analyzed separately. Fixed-effects models estimated odds ratios (ORs) with 95% confidence intervals (CIs). The primary outcome was 30-day stroke or death; secondary outcomes included peri-procedural myocardial infarction, cranial nerve injury, fatal or disabling stroke, and long-term ipsilateral stroke.
resultsTen randomized comparisons from nine trials including 14,211 patients were analyzed. In early-device trials, stroke or death occurred in 6.8% after CAS versus 4.4% after CEA (OR 1.72, 95% CI 1.41-2.10). In contemporary embolic-protected CAS-CEA trials, event rates were similarly low and no significant difference was observed (2.9% vs 3.1%; OR 1.29, 95% CI 0.98-1.70). CAS was associated with lower myocardial infarction (OR 0.47, 95% CI 0.31-0.72) and cranial nerve injury (OR 0.06, 95% CI 0.03-0.13). Long-term ipsilateral stroke rates were similar after CAS and CEA, with annualized rates of 0.64% and 0.60% per person-year, respectively (hazard ratio, 1.07; 95% CI, 0.81-1.41).
conclusionThe excess peri-procedural stroke risk associated with CAS in early trials was not observed in contemporary randomized evidence. Contemporary CAS and CEA showed similarly low peri-procedural event rates, supporting comparable safety when CAS is performed according to current procedural standards by experienced operators. These findings suggest that CAS and CEA have comparable peri-procedural safety when performed using contemporary procedural standards, supporting individualized selection of revascularization strategies.
Indexed as
Identifiers
42704462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.